B+
Bull case
25%
Probability
Target price
$14.00
Analysis reference price unavailable
Analysis 2026-04-15 · RankAlpha Sentiment Codex
CLYM
Climb BioFNasdaq / Pharmaceuticals, Biotechnology & Life Sciences
Last Price
Quote time unavailable
AI scenario view
RankAlpha Sentiment CodexMost likely
B
Base case
45%
Probability
Target price
$8.50
Analysis reference price unavailable
Analysis 2026-04-15 · RankAlpha Sentiment Codex
B-
Bear case
30%
Probability
Target price
$5.00
Analysis reference price unavailable
Analysis 2026-04-15 · RankAlpha Sentiment Codex
The current persistence contract does not provide an exact AI reference price. RankAlpha therefore does not calculate scenario return from the live quote. How scenarios are presented
AI sentiment snapshot
Latest data as of 2026-04-15
Recent news sentiment (30D)
-
Unavailable
Company
-
Unavailable
Macro
-
Unavailable
Pulse
-
Unavailable
Weekly research (10D)
-
Unavailable
Sentiment proxy
+12.5
Score
AI commentary
Sentiment is cautious-monitoring rather than outright bullish. Primary sources give clear visibility into 2026 milestones and runway, but deterministic signals still lean negative and the company remains an early-stage biotech whose investment case hinges on upcoming human data rather than current fundamentals. The comparator set is usable but not strong enough to support a standard-conviction peer-framed thesis, so CLYM still looks more like a watchlist catalyst vehicle than a high-conviction accumulation story.
RankAlpha Sentiment Codex - 2026-04-15
Open full AI memoEvidence flagged
peer set is too generic or lacks enough direct operating comparators; small-cap biotech peer set is too weak or includes unrelated comparators for a standard-conviction report
Impact
tentative
Confidence
-
AI events
2026-05-05catalystMay 5, 2026 budoprutug R&D spotlight can refine expectations but is mainly narrativeMedium impact
Climb Bio announced a May 5, 2026 R&D Spotlight webcast focused on budoprutug and the CD19 opportunity, including discussion of ongoing pMN, ITP, and SLE studies plus the recently completed subcutaneous healthy-volunteer dosing. This can sharpen investor expectations and improve program understanding, but it is not itself an efficacy datapoint [#PR-2026-04-08].
2026-06-30eventH1 to mid-2026 early readouts from subcutaneous budoprutug and CLYM116 are the next real proof pointsHigh impact
Company primary sources say the Phase 1 study of budoprutug subcutaneous formulation has completed dosing with data expected in H1 2026, while CLYM116 healthy-volunteer enrollment is ongoing with initial data expected mid-2026. These updates matter because they can validate formulation flexibility for budoprutug and establish first human PK/PD and tolerability for the APRIL program, but both remain early-stage readouts [#PR-2026-03-05] [#PR-2026-01-08].
2026-10-01catalystSecond-half 2026 initial budoprutug data across pMN, ITP, and SLE remains the core re-rating eventHigh impact
Climb's March 5, 2026 business update says all three ongoing budoprutug trials are expected to produce initial data in H2 2026, with pMN enrollment ongoing and ITP/SLE studies active. Because budoprutug is the company's lead asset and Climb remains pre-revenue, early pharmacodynamic and preliminary efficacy signals across these studies are the main determinant of whether the stock can move from monitoring setup to stronger re-rating case [#PR-2026-03-05] [#10-K-2026-03-05].
Recommendation
N/A
No formal recommendation provided.
As of 2026-04-15 • Updated nightlySource: Internal modelMethodology